{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T19:27:01Z","timestamp":1774034821442,"version":"3.50.1"},"reference-count":114,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100007161","name":"Secretaria de Investigacion y Posgrado del Instituto Polit\u00e9cnico Nacional","doi-asserted-by":"publisher","award":["SIP-20200050"],"award-info":[{"award-number":["SIP-20200050"]}],"id":[{"id":"10.13039\/501100007161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MRMC"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Type 2 diabetes mellitus (T2DM) is one of the most serious and prevalent\ndiseases worldwide. In the last decade, type 2 sodium-glucose cotransporter inhibitors (iSGLT2) were\napproved as alternative drugs for the pharmacological treatment of T2DM. The anti-hyperglycemic\nmechanism of action of these drugs involves glycosuria. In addition, SGLT2 inhibitors cause beneficial\neffects such as weight loss, a decrease in blood pressure, and others.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>This review aimed to describe the origin of SGLT2 inhibitors and analyze their recent development\nin preclinical and clinical trials.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>In 2013, the FDA approved SGLT2 inhibitors as a new alternative for the treatment of\nT2DM. These drugs have shown good tolerance with few adverse effects in clinical trials. Additionally,\nnew potential anti-T2DM agents based on iSGLT2 (O-, C-, and N-glucosides) have exhibited a\nfavorable profile in preclinical evaluations, making them candidates for advanced clinical trials.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The clinical results of SGLT2 inhibitors show the importance of this drug class as new\nanti-T2DM agents with a potential dual effect. Additionally, the preclinical results of SGLT2 inhibitors\nfavor the design and development of more selective new agents. However, several adverse effects\ncould be a potential risk for patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389557521666210805112416","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T04:12:20Z","timestamp":1628223140000},"page":"586-599","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter\nInhibitors for the Treatment of Type 2 Diabetes Mellitus"],"prefix":"10.2174","volume":"22","author":[{"given":"Ana Karen","family":"Estrada","sequence":"first","affiliation":[{"name":"Laboratorio de Biotecnolog\u00eda Farmac\u00e9utica, Centro de Biotecnolog\u00eda Gen\u00f3mica, Instituto Polit\u00e9cnico Nacional, 88710\nReynosa, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8915-7351","authenticated-orcid":true,"given":"Timoteo","family":"Delgado-Maldonado","sequence":"additional","affiliation":[{"name":"Laboratorio de Biotecnolog\u00eda Farmac\u00e9utica, Centro de Biotecnolog\u00eda Gen\u00f3mica, Instituto Polit\u00e9cnico Nacional, 88710\nReynosa, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7112-3233","authenticated-orcid":true,"given":"Edgar E.","family":"Lara-Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica de Zacatecas, Instituto Mexicano del Seguro Social (IMSS),\n98000 Zacatecas, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6144-5439","authenticated-orcid":true,"given":"Ana Ver\u00f3nica","family":"Mart\u00ednez-V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Laboratorio de Biotecnolog\u00eda Farmac\u00e9utica, Centro de Biotecnolog\u00eda Gen\u00f3mica, Instituto Polit\u00e9cnico Nacional, 88710\nReynosa, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eyra","family":"Ortiz-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Laboratorio de Biotecnolog\u00eda Farmac\u00e9utica, Centro de Biotecnolog\u00eda Gen\u00f3mica, Instituto Polit\u00e9cnico Nacional, 88710\nReynosa, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0938-6304","authenticated-orcid":true,"given":"Alma D.","family":"Paz-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Laboratorio de Biotecnolog\u00eda Farmac\u00e9utica, Centro de Biotecnolog\u00eda Gen\u00f3mica, Instituto Polit\u00e9cnico Nacional, 88710\nReynosa, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debasish","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Texas Rio Grande Valley, Edinburg, Unites States of America"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9842-4167","authenticated-orcid":true,"given":"Gildardo","family":"Rivera","sequence":"additional","affiliation":[{"name":"Laboratorio de Biotecnolog\u00eda Farmac\u00e9utica, Centro de Biotecnolog\u00eda Gen\u00f3mica, Instituto Polit\u00e9cnico Nacional, 88710\nReynosa, M\u00e9xico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"206","volume":"31","author":"Karalliedde J.","year":"2016","unstructured":"Karalliedde J.; Gnudi L.; Diabetes mellitus, a complex and heterogeneous disease, and the role of insulin resistance as a determinant of diabetic kidney disease. Nephrol Dial Transplant 2016,31(2),206-213","journal-title":"Nephrol Dial Transplant"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1590\/1980-57642016dn11-020002","volume":"11","author":"de Nazareth A.M.","year":"2017","unstructured":"de Nazareth A.M.; Type 2 diabetes mellitus in the pathophysiology of Alzheimer\u2019s disease. Dement Neuropsychol 2017,11(2),105-113","journal-title":"Dement Neuropsychol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5897\/JPAP2013.0001","volume":"4","author":"Ozougwu J.C.","year":"2013","unstructured":"Ozougwu J.C.; Obimba K.C.; Belonwu C.D.; Unakalamba C.B.; The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. J Physiol Pathophysiol 2013,4(4),46-57","journal-title":"J Physiol Pathophysiol"},{"key":"ref=4","unstructured":"World Health Organization (WHO). Diabetes. Available from: https:\/\/www.who.int\/health-topics\/diabetes#tab=tab_1"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"15019","DOI":"10.1038\/nrdp.2015.19","volume":"1","author":"DeFronzo R.A.","year":"2015","unstructured":"DeFronzo R.A.; Ferrannini E.; Groop L.; Henry R.R.; Herman W.H.; Holst J.J.; Hu F.B.; Kahn C.R.; Raz I.; Shulman G.I.; Simonson D.C.; Testa M.A.; Weiss R.; Type 2 diabetes mellitus. Nat Rev Dis Primers 2015,1,15019","journal-title":"Nat Rev Dis Primers"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-018-0703-2","volume":"17","author":"Strain W.D.","year":"2018","unstructured":"Strain W.D.; Pald\u00e1nius P.M.; Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol 2018,17(1),57","journal-title":"Cardiovasc Diabetol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/bja\/aer120","volume":"107","author":"Nicholson G.","year":"2011","unstructured":"Nicholson G.; Hall G.M.; Diabetes mellitus: New drugs for a new epidemic. Br J Anaesth 2011,107(1),65-73","journal-title":"Br J Anaesth"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.2337\/cd18-0074","volume":"37","author":"Cersosimo E.","year":"2019","unstructured":"Cersosimo E.; Lee P.G.; Pandya N.; Challenges of Diabetes Care in Older People With Type 2 Diabetes and the Role of Basal Insulin. Clin Diabetes 2019,37(4),357-367","journal-title":"Clin Diabetes"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-pharmtox-010716-104727","volume":"59","author":"Goedeke L.","year":"2019","unstructured":"Goedeke L.; Perry R.J.; Shulman G.I.; Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes. Annu Rev Pharmacol Toxicol 2019,59,65-87","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1007\/s12013-014-9998-0","volume":"70","author":"Chakraborty C.","year":"2014","unstructured":"Chakraborty C.; Hsu M.J.; Agoramoorthy G.; Understanding the molecular dynamics of type-2 diabetes drug target DPP-4 and its interaction with Sitagliptin and inhibitor Diprotin-A. Cell Biochem Biophys 2014,70(2),907-922","journal-title":"Cell Biochem Biophys"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.23736\/S0031-0808.18.03455-9","volume":"60","author":"Chellappan D.K.","year":"2018","unstructured":"Chellappan D.K.; Yap W.S.; Bt Ahmad Suhaimi N.A.; Gupta G.; Dua K.; Current therapies and targets for type 2 diabetes mellitus. Panminerva Med 2018,60(3),117-131","journal-title":"Panminerva Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","volume":"10","author":"Khan M.A.B.","year":"2020","unstructured":"Khan M.A.B.; Hashim M.J.; King J.K.; Govender R.D.; Mustafa H.; Al Kaabi J.; Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. J Epidemiol Glob Health 2020,10(1),107-111","journal-title":"J Epidemiol Glob Health"},{"key":"ref=13","unstructured":"International Federation Diabetes (IDF). Available from: https:\/\/idf.org\/"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.chest.2017.11.040","volume":"153","author":"Pan S.W.","year":"2018","unstructured":"Pan S.W.; Yen Y.F.; Kou Y.R.; Chuang P.H.; Su V.Y.; Feng J.Y.; Chan Y.J.; Su W.J.; The Risk of TB in Patients With Type 2 Diabetes Initiating Metformin vs Sulfonylurea Treatment. Chest 2018,153(6),1347-1357","journal-title":"Chest"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2337\/diacare.27.1.141","volume":"27","author":"Hanefeld M.","year":"2004","unstructured":"Hanefeld M.; Brunetti P.; Schernthaner G.H.; Matthews D.R.; Charbonnel B.H.; One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004,27(1),141-147","journal-title":"Diabetes Care"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/jdi.13090","volume":"10","author":"Hotta N.","year":"2019","unstructured":"Hotta N.; A new perspective on the biguanide, metformin therapy in type 2 diabetes and lactic acidosis. J Diabetes Investig 2019,10(4),906-908","journal-title":"J Diabetes Investig"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/molecules25081987","volume":"25","author":"Artasensi A.","year":"2020","unstructured":"Artasensi A.; Pedretti A.; Vistoli G.; Fumagalli L.; Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules 2020,25(8),1987","journal-title":"Molecules"},{"key":"ref=18","doi-asserted-by":"publisher","DOI":"10.1016\/j.carres.2020.108220","volume":"499","author":"Szab\u00f3 K.","year":"2021","unstructured":"Szab\u00f3 K.; Maccari R.; Ottan\u00e0 R.; Gy\u00e9m\u00e1nt G.; Extending the investigation of 4-thiazolidinone derivatives as potential multi-target ligands of enzymes involved in diabetes mellitus and its long-term complications: A study with pancreatic \u03b1-amylase. Carbohydr Res 2021,499","journal-title":"Carbohydr Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1463-1326.2008.01031.x","volume":"11","author":"Bosi E.","year":"2009","unstructured":"Bosi E.; Metformin--the gold standard in type 2 diabetes: What does the evidence tell us? Diabetes Obes Metab 2009,11(Suppl. 2),3-8","journal-title":"Diabetes Obes Metab"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2337\/dc12-0719","volume":"36","author":"Hong J.","year":"2013","unstructured":"Hong J.; Zhang Y.; Lai S.; Lv A.; Su Q.; Dong Y.; Zhou Z.; Tang W.; Zhao J.; Cui L.; Zou D.; Wang D.; Li H.; Liu C.; Wu G.; Shen J.; Zhu D.; Wang W.; Shen W.; Ning G.; Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013,36(5),1304-1311","journal-title":"Diabetes Care"},{"key":"ref=21","first-page":"5","volume":"150","author":"Z\u00e1rate A.","year":"2014","unstructured":"Z\u00e1rate A.; Islas S.; Saucedo R.; Eficacia y effectos adversos de los antidiab\u00e9ticos orales. Gac Med Mex 2014,150(1),5-7","journal-title":"Gac Med Mex"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.metabol.2015.10.014","volume":"65","author":"DeFronzo R.","year":"2016","unstructured":"DeFronzo R.; Fleming G.A.; Chen K.; Bicsak T.A.; Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism 2016,65(2),20-29","journal-title":"Metabolism"},{"key":"ref=23","unstructured":"FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function The U.S. Food and Drug Administration (FDA)","journal-title":"FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2337\/diacare.28.1.154","volume":"28","author":"van de Laar F.A.","year":"2005","unstructured":"van de Laar F.A.; Lucassen P.L.; Akkermans R.P.; van de Lisdonk E.H.; Rutten G.E.; van Weel C.; Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005,28(1),154-163","journal-title":"Diabetes Care"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00580-014-1967-x","volume":"25","author":"Mahmood N.","year":"2014","unstructured":"Mahmood N.; A review of \u03b1-amylase inhibitors on weight loss and glycemic control in pathological state such as obesity and diabetes. Comp Clin Pathol 2014,25(6),1253-1264","journal-title":"Comp Clin Pathol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/jdi.12711","volume":"9","author":"Gao X.","year":"2018","unstructured":"Gao X.; Cai X.; Yang W.; Chen Y.; Han X.; Ji L.; Meta-analysis and critical review on the efficacy and safety of alpha-glucosidase inhibitors in Asian and non-Asian populations. J Diabetes Investig 2018,9(2),321-331","journal-title":"J Diabetes Investig"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.18433\/J35S3K","volume":"15","author":"Sales P.M.","year":"2012","unstructured":"Sales P.M.; Souza P.M.; Simeoni L.A.; Silveira D.; Silveira D.; \u03b1-Amylase inhibitors: A review of raw material and isolated compounds from plant source. J Pharm Pharm Sci 2012,15(1),141-183","journal-title":"J Pharm Pharm Sci"},{"key":"ref=28","first-page":"202","volume":"17","author":"Kumar S.R.S.","year":"2018","unstructured":"Kumar S.R.S.; Rao K.V.B.; Efficacy of Alpha Glucosidase Inhibitor from Marine Actinobacterium in the Control of Postprandial Hyperglycaemia in Streptozotocin (STZ) Induced Diabetic Male Albino Wister Rats. Iran J Pharm Res 2018,17(1),202-214","journal-title":"Iran J Pharm Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"32649","DOI":"10.1038\/srep32649","volume":"6","author":"Zhang L.","year":"2016","unstructured":"Zhang L.; Chen Q.; Li L.; Kwong J.S.; Jia P.; Zhao P.; Wang W.; Zhou X.; Zhang M.; Sun X.; Alpha-glucosidase inhibitors and hepatotoxicity in type 2 diabetes: A systematic review and meta-analysis. Sci Rep 2016,6,32649","journal-title":"Sci Rep"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00198-020-05791-5","volume":"32","author":"Kreitman A.","year":"2021","unstructured":"Kreitman A.; Schneider S.H.; Hao L.; Schlussel Y.; Bello N.T.; Shapses S.A.; Reduced postprandial bone resorption and greater rise in GLP-1 in overweight and obese individuals after an \u03b1-glucosidase inhibitor: A double-blinded randomized crossover trial. Osteoporos Int 2021,32(7),1379-1386","journal-title":"Osteoporos Int"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1507\/endocrj.EJ19-0041","volume":"66","author":"Aoki K.","year":"2019","unstructured":"Aoki K.; Sato H.; Terauchi Y.; Usefulness of antidiabetic alpha-glucosidase inhibitors: A review on the timing of administration and effects on gut hormones. Endocr J 2019,66(5),395-401","journal-title":"Endocr J"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1210\/jc.2010-2049","volume":"95","author":"Perseghin G.","year":"2010","unstructured":"Perseghin G.; Exploring the vitro mechanisms of action of glucokinase activators in type 2 diabetes. J Clin Endocrinol Metab 2010,95(11),4871-4873","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s40265-020-01278-z","volume":"80","author":"Toulis K.A.","year":"2020","unstructured":"Toulis K.A.; Nirantharakumar K.; Pourzitaki C.; Barnett A.H.; Tahrani A.A.; Glucokinase Activators for Type 2 Diabetes: Challenges and Future Developments. Drugs 2020,80(5),467-475","journal-title":"Drugs"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1517\/13543776.2014.965680","volume":"24","author":"Agius L.","year":"2014","unstructured":"Agius L.; Lessons from glucokinase activators: The problem of declining efficacy. Expert Opin Ther Pat 2014,24(11),1155-1159","journal-title":"Expert Opin Ther Pat"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1463-1326.2011.01511.x","volume":"14","author":"DeFronzo R.A.","year":"2012","unstructured":"DeFronzo R.A.; Davidson J.A.; Del Prato S.; The role of the kidneys in glucose homeostasis: A new path towards normalizing glycaemia. Diabetes Obes Metab 2012,14(1),5-14","journal-title":"Diabetes Obes Metab"},{"key":"ref=36","first-page":"618","volume":"6","author":"P\u00e9rez-L\u00f3pez G.","year":"2010","unstructured":"P\u00e9rez-L\u00f3pez G.; Gonz\u00e1lez-Albarr\u00e1n O.; Cano-Meg\u00edas M.; Sodium-\nglucose cotransporter type 2 inhibitors (SGLT2): From familial\nrenal glucosuria to the treatment of type 2 diabetes mellitusRevista\nNefrolog\u00eda, 2010,6,618-625"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1586\/17512433.2013.827399","volume":"6","author":"Andrianesis V.","year":"2013","unstructured":"Andrianesis V.; Doupis J.; The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment. Expert Rev Clin Pharmacol 2013,6(5),519-539","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/MNH.0000000000000152","volume":"24","author":"Poulsen S.B.","year":"2015","unstructured":"Poulsen S.B.; Fenton R.A.; Rieg T.; Sodium-glucose cotransport. Curr Opin Nephrol Hypertens 2015,24(5),463-469","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","volume":"61","author":"Ghezzi C.","year":"2018","unstructured":"Ghezzi C.; Loo D.D.F.; Wright E.M.; Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia 2018,61(10),2087-2097","journal-title":"Diabetologia"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","volume":"61","author":"Thomas M.C.","year":"2018","unstructured":"Thomas M.C.; Cherney D.Z.I.; The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 2018,61(10),2098-2107","journal-title":"Diabetologia"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2337\/db12-0052","volume":"61","author":"Liu J.J.","year":"2012","unstructured":"Liu J.J.; Lee T.; DeFronzo R.A.; Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes 2012,61(9),2199-2204","journal-title":"Diabetes"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.recesp.2016.07.029","volume":"69","author":"Dalama B.","year":"2016","unstructured":"Dalama B.; Mesa J.; New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border. Rev Esp Cardiol 2016,69(11),1088-1097","journal-title":"Rev Esp Cardiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2215\/CJN.06080616","volume":"12","author":"van Bommel E.J.","year":"2017","unstructured":"van Bommel E.J.; Muskiet M.H.; Tonneijck L.; Kramer M.H.; Nieuwdorp M.; van Raalte D.H.; SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome. Clin J Am Soc Nephrol 2017,12(4),700-710","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","volume":"61","author":"Rieg T.","year":"2018","unstructured":"Rieg T.; Vallon V.; Development of SGLT1 and SGLT2 inhibitors. Diabetologia 2018,61(10),2079-2086","journal-title":"Diabetologia"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1681\/ASN.2010030246","volume":"22","author":"Vallon V.","year":"2011","unstructured":"Vallon V.; Platt K.A.; Cunard R.; Schroth J.; Whaley J.; Thomson S.C.; Koepsell H.; Rieg T.; SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011,22(1),104-112","journal-title":"J Am Soc Nephrol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2147\/DDDT.S144556","volume":"13","author":"Rendell M.S.","year":"2019","unstructured":"Rendell M.S.; The journey from gene knockout to clinical medicine: Telotristat and sotagliflozin. Drug Des Devel Ther 2019,13(13),817-824","journal-title":"Drug Des Devel Ther"},{"key":"ref=47","unstructured":"Diabetes Education Online \u2013 University of California. Available from: https:\/\/dtc.ucsf.edu\/types-of-diabetes\/type2\/treatment-of-type-2-diabetes\/medications-and-therapies\/type-2-non-insulin-therapies\/table-of-medications\/"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"Verma S.","year":"2018","unstructured":"Verma S.; McMurray J.J.V.; SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review. Diabetologia 2018,61(10),2108-2117","journal-title":"Diabetologia"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"Zelniker T.A.","year":"2019","unstructured":"Zelniker T.A.; Wiviott S.D.; Raz I.; Im, K.; Goodrich, E.L.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Furtado, R.H.M.; Bhatt, D.L.; Leiter, L.A.; McGuire, D.K.; Wilding, J.P.H.; Sabatine, M.S. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019,393(10166),31-39","journal-title":"Lancet"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/DMSO.S233538","volume":"13","author":"Bonora B.M.","year":"2020","unstructured":"Bonora B.M.; Avogaro A.; Fadini G.P.; Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence. Diabetes Metab Syndr Obes 2020,13,161-174","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"Ehrenkranz J.R.","year":"2005","unstructured":"Ehrenkranz J.R.; Lewis N.G.; Kahn C.R.; Roth J.; Phlorizin: A review. Diabetes Metab Res Rev 2005,21(1),31-38","journal-title":"Diabetes Metab Res Rev"},{"key":"ref=52","first-page":"235","volume":"27","author":"Aylwin H.C.G.","year":"2016","unstructured":"Aylwin H.C.G.; New Drugs For Treatment Of Diabetes Mellitus. Rev Med Clin Las Condes 2016,27(2),235-256","journal-title":"Rev Med Clin Las Condes"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1021\/jm8013019","volume":"52","author":"Washburn W.N.","year":"2009","unstructured":"Washburn W.N.; Development of the renal glucose reabsorption inhibitors: A new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 2009,52(7),1785-1794","journal-title":"J Med Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1038\/ki.2010.511","author":"Isaji M.","year":"2011","unstructured":"Isaji M.; SGLT2 inhibitors: Molecular design and potential differences in effect. Kidney Int Suppl 2011(120),S14-S19","journal-title":"Kidney Int Suppl"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1517\/13543784.2013.740009","volume":"22","author":"Paisley A.N.","year":"2013","unstructured":"Paisley A.N.; Yadav R.; Younis N.; Rao-Balakrishna P.; Soran H.; Dapagliflozin: A review on efficacy, clinical effectiveness and safety. Expert Opin Investig Drugs 2013,22(1),131-140","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","volume":"8","author":"Ferrannini E.","year":"2012","unstructured":"Ferrannini E.; Solini A.; SGLT2 inhibition in diabetes mellitus: Rationale and clinical prospects. Nat Rev Endocrinol 2012,8(8),495-502","journal-title":"Nat Rev Endocrinol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0014-2999(00)00016-9","volume":"391","author":"Oku A.","year":"2000","unstructured":"Oku A.; Ueta K.; Nawano M.; Arakawa K.; Kano-Ishihara T.; Matsumoto M.; Saito A.; Tsujihara K.; Anai M.; Asano T.; Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol 2000,391(1-2),183-192","journal-title":"Eur J Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1046\/j.1440-1681.2002.03671.x","volume":"29","author":"Nunoi K.","year":"2002","unstructured":"Nunoi K.; Yasuda K.; Adachi T.; Okamoto Y.; Shihara N.; Uno M.; Tamon A.; Suzuki N.; Oku A.; Tsuda K.; Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 2002,29(5-6),386-390","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/B978-0-12-409547-2.12430-8","volume":"Vol. 1","author":"Bebernitz G.","year":"2017","unstructured":"Bebernitz G.;  In:Comprehensive Medicinal Chemistry III 2017,Vol. 1,491-511","journal-title":"In:Comprehensive Medicinal Chemistry III"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1124\/jpet.108.140210","volume":"327","author":"Fujimori Y.","year":"2008","unstructured":"Fujimori Y.; Katsuno K.; Nakashima I.; Ishikawa-Takemura Y.; Fujikura H.; Isaji M.; Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008,327(1),268-276","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.2147\/DDDT.S221093","volume":"14","author":"Mohan V.","year":"2020","unstructured":"Mohan V.; Mithal A.; Joshi S.R.; Aravind S.R.; Chowdhury S.; Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy. Drug Des Devel Ther 2020,14,2487-2501","journal-title":"Drug Des Devel Ther"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40265-019-01150-9","volume":"79","author":"Markham A.","year":"2019","unstructured":"Markham A.; Remogliflozin Etabonate: First Global Approval. Drugs 2019,79(10),1157-1161","journal-title":"Drugs"},{"key":"ref=63","first-page":"209","volume":"12","author":"Jakher H.","year":"2019","unstructured":"Jakher H.; Chang T.I.; Tan M.; Mahaffey K.W.; Canagliflozin review - safety and efficacy profile in patients with T2DM. Diabetes\nMetab Syndr Obes: Targets and therapy, 2019,12,209-215"},{"key":"ref=64","unstructured":"Drugbank. Canaglifozin. Available from:  https:\/\/go.drugbank.com\/drugs\/DB08907"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"Perkovic V.","year":"2019","unstructured":"Perkovic V.; Jardine M.J.; Neal B.; Bompoint S.; Heerspink H.J.L.; Charytan D.M.; Edwards R.; Agarwal R.; Bakris G.; Bull S.; Cannon C.P.; Capuano G.; Chu P.L.; de Zeeuw D.; Greene T.; Levin A.; Pollock C.; Wheeler D.C.; Yavin Y.; Zhang H.; Zinman B.; Meininger G.; Brenner B.M.; Mahaffey K.W.; Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019,380(24),2295-2306","journal-title":"N Engl J Med"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.3390\/ijms20205237","volume":"20","author":"Jojima T.","year":"2019","unstructured":"Jojima T.; Wakamatsu S.; Kase M.; Iijima T.; Maejima Y.; Shimomura K.; Kogai T.; Tomaru T.; Usui I.; Aso Y.; The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma. Int J Mol Sci 2019,20(20),5237","journal-title":"Int J Mol Sci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2146\/ajhp140168","volume":"72","author":"Vivian E.M.","year":"2015","unstructured":"Vivian E.M.; Dapagliflozin: A new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. Am J Health Syst Pharm 2015,72(5),361-372","journal-title":"Am J Health Syst Pharm"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1007\/s40265-019-01148-3","volume":"79","author":"Dhillon S.","year":"2019","unstructured":"Dhillon S.; Dapagliflozin: A Review in Type 2 Diabetes. Drugs 2019,79(10),1135-1146","journal-title":"Drugs"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"399","DOI":"10.12669\/pjms.35.2.21","volume":"35","author":"Sertbas M.","year":"2019","unstructured":"Sertbas M.; Sertbas Y.; Okuroglu N.; Akyildiz A.B.; Sancak S.; Ozdemir A.; Eff\u0131cacy and safety of dapagliflozin on diabetic patients receiving high-doses of insulin. Pak J Med Sci 2019,35(2),399-403","journal-title":"Pak J Med Sci"},{"key":"ref=70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2021.109368","volume":"335","author":"Arab H.H.","year":"2021","unstructured":"Arab H.H.; Al-Shorbagy M.Y.; Saad M.A.; Activation of autophagy and suppression of apoptosis by dapagliflozin attenuates experimental inflammatory bowel disease in rats: Targeting AMPK\/mTOR, HMGB1\/RAGE and Nrf2\/HO-1 pathways. Chem Biol Interact 2021,335","journal-title":"Chem Biol Interact"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1016\/j.bmc.2010.01.073","volume":"18","author":"Lee J.","year":"2010","unstructured":"Lee J.; Lee S.H.; Seo H.J.; Son E.J.; Lee S.H.; Jung M.E.; Lee M.; Han H.K.; Kim J.; Kang J.; Lee J.; Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners. Bioorg Med Chem 2010,18(6),2178-2194","journal-title":"Bioorg Med Chem"},{"key":"ref=72","first-page":"34","volume":"34","author":"G\u00f3mez-Huelgas R.","year":"2014","unstructured":"G\u00f3mez-Huelgas R.; Mart\u00ednez-Castelao A.; Artola S.; G\u00f3rriz J.L.; Men\u00e9ndez E.; Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease. Nefrologia 2014,34(1),34-45","journal-title":"Nefrologia"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1111\/dom.13413","volume":"20","author":"Fioretto P.","year":"2018","unstructured":"Fioretto P.; Del Prato S.; Buse J.B.; Goldenberg R.; Giorgino F.; Reyner D.; Langkilde A.M.; Sj\u00f6str\u00f6m C.D.; Sartipy P.; Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study. Diabetes Obes Metab 2018,20(11),2532-2540","journal-title":"Diabetes Obes Metab"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"McMurray J.J.V.","year":"2019","unstructured":"McMurray J.J.V.; Solomon S.D.; Inzucchi S.E.; K\u00f8ber L.; Kosiborod M.N.; Martinez F.A.; Ponikowski P.; Sabatine M.S.; Anand I.S.; B\u011blohl\u00e1vek J.; B\u00f6hm M.; Chiang C.E.; Chopra V.K.; de Boer R.A.; Desai A.S.; Diez M.; Drozdz J.; Duk\u00e1t A.; Ge J.; Howlett J.G.; Katova T.; Kitakaze M.; Ljungman C.E.A.; Merkely B.; Nicolau J.C.; O\u2019Meara E.; Petrie M.C.; Vinh P.N.; Schou M.; Tereshchenko S.; Verma S.; Held C.; DeMets D.L.; Docherty K.F.; Jhund P.S.; Bengtsson O.; Sj\u00f6strand M.; Langkilde A.M.; Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019,381(21),1995-2008","journal-title":"N Engl J Med"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","volume":"14","author":"Grempler R.","year":"2012","unstructured":"Grempler R.; Thomas L.; Eckhardt M.; Himmelsbach F.; Sauer A.; Sharp D.E.; Bakker R.A.; Mark M.; Klein T.; Eickelmann P.; Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012,14(1),83-90","journal-title":"Diabetes Obes Metab"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1517\/14656566.2014.966078","volume":"15","author":"Jahagirdar V.","year":"2014","unstructured":"Jahagirdar V.; Barnett A.H.; Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2014,15(16),2429-2441","journal-title":"Expert Opin Pharmacother"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ijcard.2016.11.181","volume":"228","author":"Saad M.","year":"2017","unstructured":"Saad M.; Mahmoud A.N.; Elgendy I.Y.; Abuzaid A.; Barakat A.F.; Elgendy A.Y.; Al-Ani M.; Mentias A.; Nairooz R.; Bavry A.A.; Mukherjee D.; Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. Int J Cardiol 2017,228,352-358","journal-title":"Int J Cardiol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"Zinman B.","year":"2015","unstructured":"Zinman B.; Wanner C.; Lachin J.M.; Fitchett D.; Bluhmki E.; Hantel S.; Mattheus M.; Devins T.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Inzucchi S.E.; Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015,373(22),2117-2128","journal-title":"N Engl J Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"Wanner C.","year":"2016","unstructured":"Wanner C.; Inzucchi S.E.; Lachin J.M.; Fitchett D.; von Eynatten M.; Mattheus M.; Johansen O.E.; Woerle H.J.; Broedl U.C.; Zinman B.; Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016,375(4),323-334","journal-title":"N Engl J Med"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1021\/ol100940w","volume":"12","author":"Mascitti V.","year":"2010","unstructured":"Mascitti V.; Pr\u00e9ville C.; Stereoselective synthesis of a dioxa-bicyclo[3.2.1]octane SGLT2 inhibitor. Org Lett 2010,12(13),2940-2943","journal-title":"Org Lett"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1021\/jm200049r","volume":"54","author":"Mascitti V.","year":"2011","unstructured":"Mascitti V.; Maurer T.S.; Robinson R.P.; Bian J.; Boustany-Kari C.M.; Brandt T.; Collman B.M.; Kalgutkar A.S.; Klenotic M.K.; Leininger M.T.; Lowe A.; Maguire R.J.; Masterson V.M.; Miao Z.; Mukaiyama E.; Patel J.D.; Pettersen J.C.; Pr\u00e9ville C.; Samas B.; She L.; Sobol Z.; Steppan C.M.; Stevens B.D.; Thuma B.A.; Tugnait M.; Zeng D.; Zhu T.; Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem 2011,54(8),2952-2960","journal-title":"J Med Chem"},{"key":"ref=82","unstructured":"Pfizer News. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/fda_approves_sglt2_inhibitor_steglatro_ertugliflozin_and_fixed_dose_combination_steglujan_ertugliflozin_and_sitagliptin_for_adults_with_type_2_diabetes"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1007\/s40262-020-00875-1","volume":"59","author":"Fediuk D.J.","year":"2020","unstructured":"Fediuk D.J.; Nucci G.; Dawra V.K.; Cutler D.L.; Amin N.B.; Terra S.G.; Boyd R.A.; Krishna R.; Sahasrabudhe V.; Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2). Inhibitor Clin Pharmacokinet 2020,59(8),949-965","journal-title":"Inhibitor Clin Pharmacokinet"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1124\/dmd.112.049551","volume":"41","author":"Miao Z.","year":"2013","unstructured":"Miao Z.; Nucci G.; Amin N.; Sharma R.; Mascitti V.; Tugnait M.; Vaz A.D.; Callegari E.; Kalgutkar A.S.; Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos 2013,41(2),445-456","journal-title":"Drug Metab Dispos"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"Cannon C.P.","year":"2020","unstructured":"Cannon C.P.; Pratley R.; Dagogo-Jack S.; Mancuso J.; Huyck S.; Masiukiewicz U.; Charbonnel B.; Frederich R.; Gallo S.; Cosentino F.; Shih W.J.; Gantz I.; Terra S.G.; Cherney D.Z.I.; McGuire D.K.; Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020,383(15),1425-1435","journal-title":"N Engl J Med"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40265-014-0204-x","volume":"74","author":"Poole R.M.","year":"2014","unstructured":"Poole R.M.; Dungo R.T.; Ipragliflozin: First global approval. Drugs 2014,74(5),611-617","journal-title":"Drugs"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/dom.12331","volume":"17","author":"Kashiwagi A.","year":"2015","unstructured":"Kashiwagi A.; Kazuta K.; Goto K.; Yoshida S.; Ueyama E.; Utsuno A.; Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2015,17(3),304-308","journal-title":"Diabetes Obes Metab"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s13300-019-00699-8","volume":"10","author":"Kashiwagi A.","year":"2019","unstructured":"Kashiwagi A.; Shestakova M.V.; Ito Y.; Noguchi M.; Wilpshaar W.; Yoshida S.; Wilding J.P.H.; Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II\/III\/IV Clinical Trials. Diabetes Ther 2019,10(6),2201-2217","journal-title":"Diabetes Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1124\/jpet.112.191593","volume":"341","author":"Suzuki M.","year":"2012","unstructured":"Suzuki M.; Honda K.; Fukazawa M.; Ozawa K.; Hagita H.; Kawai T.; Takeda M.; Yata T.; Kawai M.; Fukuzawa T.; Kobayashi T.; Sato T.; Kawabe Y.; Ikeda S.; Tofogliflozin, a potent and highly specific sodium\/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther 2012,341(3),692-701","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=90","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/6470137","volume":"2018","author":"Kamei S.","year":"2018","unstructured":"Kamei S.; Iwamoto M.; Kameyama M.; Shimoda M.; Kinoshita T.; Obata A.; Kimura T.; Hirukawa H.; Tatsumi F.; Kohara K.; Nakanishi S.; Mune T.; Kaku K.; Kaneto H.; Effect of Tofogliflozin on Body Composition and Glycemic Control in Japanese Subjects with Type 2 Diabetes Mellitus. J Diabetes Res 2018,2018","journal-title":"J Diabetes Res"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/jdi.13122","volume":"11","author":"Tochiya M.","year":"2020","unstructured":"Tochiya M.; Makino H.; Tamanaha T.; Matsuo M.; Hishida A.; Koezuka R.; Ohata Y.; Tomita T.; Son C.; Miyamoto Y.; Yasuda S.; Hosoda K.; Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study. J Diabetes Investig 2020,11(2),400-404","journal-title":"J Diabetes Investig"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1177\/0091270009352185","volume":"50","author":"Hussey E.K.","year":"2010","unstructured":"Hussey E.K.; Dobbins R.L.; Stoltz R.R.; Stockman N.L.; O\u2019Connor-Semmes R.L.; Kapur A.; Murray S.C.; Layko D.; Nunez D.J.; Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: A randomized double-blind study. J Clin Pharmacol 2010,50(6),636-646","journal-title":"J Clin Pharmacol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/13543784.2019.1655539","volume":"28","author":"Adeghate E.","year":"2019","unstructured":"Adeghate E.; Mohsin S.; Adi F.; Ahmed F.; Yahya A.; Kal\u00e1sz H.; Tekes K.; Adeghate E.A.; An update of SGLT1 and SGLT2 inhibitors in early phase diabetes-type 2 clinical trials. Expert Opin Investig Drugs 2019,28(9),811-820","journal-title":"Expert Opin Investig Drugs"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/dom.13745","volume":"21","author":"Dicembrini I.","year":"2019","unstructured":"Dicembrini I.; Nreu B.; Mannucci E.; Monami M.; Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials. Diabetes Obes Metab 2019,21(8),1871-1877","journal-title":"Diabetes Obes Metab"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.bmcl.2016.03.065","volume":"26","author":"Cao X.","year":"2016","unstructured":"Cao X.; Zhang W.; Yan X.; Huang Z.; Zhang Z.; Wang P.; Shen J.; Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design. Bioorg Med Chem Lett 2016,26(9),2170-2173","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1021\/jm901893x","volume":"53","author":"Kakinuma H.","year":"2010","unstructured":"Kakinuma H.; Oi T.; Hashimoto-Tsuchiya Y.; Arai M.; Kawakita Y.; Fukasawa Y.; Iida I.; Hagima N.; Takeuchi H.; Chino Y.; Asami J.; Okumura-Kitajima L.; Io F.; Yamamoto D.; Miyata N.; Takahashi T.; Uchida S.; Yamamoto K.; (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010,53(8),3247-3261","journal-title":"J Med Chem"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1185\/03007995.2014.901943","volume":"30","author":"Seino Y.","year":"2014","unstructured":"Seino Y.; Sasaki T.; Fukatsu A.; Sakai S.; Samukawa Y.; Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A 12-week, randomized, placebo-controlled, phase II study. Curr Med Res Opin 2014,30(7),1219-1230","journal-title":"Curr Med Res Opin"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1080\/14740338.2017.1359252","volume":"16","author":"Yabe D.","year":"2017","unstructured":"Yabe D.; Hamamoto Y.; Seino Y.; Kuwata H.; Kurose T.; Seino Y.; Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: A drug safety evaluation. Expert Opin Drug Saf 2017,16(10),1211-1218","journal-title":"Expert Opin Drug Saf"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.bmcl.2018.04.070","volume":"28","author":"Zhao X.","year":"2018","unstructured":"Zhao X.; Sun B.; Zheng H.; Liu J.; Qian L.; Wang X.; Lou H.; Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Bioorg Med Chem Lett 2018,28(12),2201-2205","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1016\/j.bmcl.2018.09.025","volume":"28","author":"Xu G.","year":"2018","unstructured":"Xu G.; Gaul M.D.; Kuo G.H.; Du F.; Xu J.Z.; Wallace N.; Hinke S.; Kirchner T.; Silva J.; Huebert N.D.; Lee S.; Murray W.; Liang Y.; Demarest K.; Design, synthesis and biological evaluation of (2S,3R,4R,5S,6R)-5-fluoro-6-(hydroxymethyl)-2-aryltetrahydro-2H-pyran-3,4-diols as potent and orally active SGLT dual inhibitors. Bioorg Med Chem Lett 2018,28(21),3446-3453","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1016\/j.bmc.2018.06.017","volume":"26","author":"Li Z.","year":"2018","unstructured":"Li Z.; Xu X.; Deng L.; Liao R.; Liang R.; Zhang B.; Zhang L.; Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents. Bioorg Med Chem 2018,26(14),3947-3952","journal-title":"Bioorg Med Chem"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ejmech.2019.07.032","volume":"180","author":"Wang Y.","year":"2019","unstructured":"Wang Y.; Lou Y.; Wang J.; Li D.; Chen H.; Zheng T.; Xia C.; Song X.; Dong T.; Li J.; Li J.; Liu H.; Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. Eur J Med Chem 2019,180,398-416","journal-title":"Eur J Med Chem"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.bioorg.2018.11.006","volume":"83","author":"Chu K.F.","year":"2019","unstructured":"Chu K.F.; Song J.S.; Chen C.T.; Yeh T.K.; Hsieh T.C.; Huang C.Y.; Wang M.H.; Wu S.H.; Yao C.H.; Chao Y.S.; Lee J.C.; Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors. Bioorg Chem 2019,83,520-525","journal-title":"Bioorg Chem"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.nefroe.2018.03.007","volume":"38","author":"Marques Vidas M.","year":"2018","unstructured":"Marques Vidas M.; Dura Gurpide B.; Rubio E.; Huerta A.; Portol\u00e9s P\u00e9rez J.; Hipercalcemia inducida por dapagliflozina. Nefrologia (Engl Ed) 2018,38(3),336-337","journal-title":"Nefrologia (Engl Ed)"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"Heerspink H.J.","year":"2016","unstructured":"Heerspink H.J.; Perkins B.A.; Fitchett D.H.; Husain M.; Cherney D.Z.; Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation 2016,134(10),752-772","journal-title":"Circulation"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"213","DOI":"10.25179\/tjem.2017-56553","volume":"22","author":"Imga N.N.","year":"2018","unstructured":"Imga N.N.; \u00c7atak M.; Berker D.; Dapagliflozin-induced vulvovaginitis in an atopic patient with type 2 diabetes mellitus. Turkish Journal of Endocrinology and Metabolism 2018,22(3),213-216","journal-title":"Turkish Journal of Endocrinology and Metabolism"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/IPC.0000000000000588","volume":"26","author":"Fox L.","year":"2018","unstructured":"Fox L.; Nelson A.C.; Ghanem G.; Candida krusei Emphysematous Pyelonephritis Possibly Due to Dapagliflozin Therapy. Infect Dis Clin Pract 2018,26(6),363-365","journal-title":"Infect Dis Clin Pract"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1186\/s12879-021-05982-3","volume":"21","author":"Bartolo C.","year":"2021","unstructured":"Bartolo C.; Hall V.; Friedman N.D.; Lanyon C.; Fuller A.; Morrissey C.O.; Athan E.; Bittersweet: Infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: Two case reports. BMC Infect Dis 2021,21(1),284","journal-title":"BMC Infect Dis"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.15406\/jdmdc.2019.06.00178","volume":"6","author":"Maideen N.M.P.","year":"2019","unstructured":"Maideen N.M.P.; Pharmacologically relevant drug interactions of \u03b1-glucosidase inhibitors. J Diabetes Metab Disord Cont 2019,6(2),28-30","journal-title":"J Diabetes Metab Disord Cont"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40265-017-0697-1","volume":"77","author":"Garnock-Jones K.P.","year":"2017","unstructured":"Garnock-Jones K.P.; Saxagliptin\/Dapagliflozin: A Review in Type 2 Diabetes Mellitus. Drugs 2017,77(3),319-330","journal-title":"Drugs"},{"key":"ref=111","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99123","volume":"3","author":"Blau J.E.","year":"2018","unstructured":"Blau J.E.; Bauman V.; Conway E.M.; Piaggi P.; Walter M.F.; Wright E.C.; Bernstein S.; Courville A.B.; Collins M.T.; Rother K.I.; Taylor S.I.; Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 2018,3(8)","journal-title":"JCI Insight"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-018-0028-0","volume":"14","author":"Blau J.E.","year":"2018","unstructured":"Blau J.E.; Taylor S.I.; Adverse effects of SGLT2 inhibitors on bone health. Nat Rev Nephrol 2018,14(8),473-474","journal-title":"Nat Rev Nephrol"},{"key":"ref=113","year":"2018","unstructured":"The US Food and Drug Administration (FDA) FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes 2018","journal-title":"The US Food and Drug Administration (FDA) FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s40261-018-0731-4","volume":"39","author":"Kaneko M.","year":"2019","unstructured":"Kaneko M.; Narukawa M.; Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio. Clin Drug Investig 2019,39(2),179-186","journal-title":"Clin Drug Investig"}],"container-title":["Mini-Reviews in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557521666210805112416","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/195301\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389557521666210805112416","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T05:28:51Z","timestamp":1656566931000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/195301\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":114,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389557521666210805112416","relation":{},"ISSN":["1389-5575"],"issn-type":[{"value":"1389-5575","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}